Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919633 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
A Phase 2 study of Hepatitis C, sponsored by Medtronic Corporate Technologies and New Ventures.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT00919633 is a Phase 2 study of Hepatitis C that has completed, run by Medtronic Corporate Technologies and New Ventures. The registered enrollment target is 116 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00919633, a Phase 2 study of Hepatitis C, has completed, sponsored by Medtronic Corporate Technologies and New Ventures.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with chronic hepatitis C infection as compared to patients who receive standard treatment.
Conditions Studied
Interventions
- DRUG interferon alfa-2b
- DRUG peginterferon alfa-2b
- DRUG ribavirin, USP
- DEVICE external drug infusion pump
Study Locations (1)
North Carolina
- Duke Clinical Research Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00919633
The ClinicalTrials.gov registry entry for NCT00919633 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The listed sponsor is Medtronic Corporate Technologies and New Ventures, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 4 interventions - of which interferon alfa-2b is the first listed.
NCT00919633 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00919633 about?
NCT00919633 is a clinical study titled "Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C". The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with chronic hepatitis C infection as compared to patients who receive stan...
What is the current status of trial NCT00919633?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2009-06. Estimated completion is 2012-07.
What conditions does trial NCT00919633 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00919633?
The interventions under investigation include: interferon alfa-2b (DRUG), peginterferon alfa-2b (DRUG), ribavirin, USP (DRUG), external drug infusion pump (DEVICE).
Who is sponsoring clinical trial NCT00919633?
This trial is sponsored by Medtronic Corporate Technologies and New Ventures, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00919633 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.